The U.S. Food and Drug Administration (FDA) Advisory Committee has scheduled apublic meeting on February 15 to discuss Pfizer’s request for emergency authorization to allow children older than six months old but younger than five years old to receive their two-dose COVID-19 vaccination series.
In late December, Pfizer announced its two-dose series provided to 2- to 4-year-olds had not been shown to be effective and was testing a third shot. The two-dose series did appear to be effective, however, for children aged 6 months to 2 years. In an unusual move, Pfizer is asking the FDA Advisory Committeeto authorize two doses of their vaccine for children younger than 5 while research continues on the efficacy of three doses for the age group.
Stay Informed on the Latest Research & Analysis from ANCOR